Recent Quotes
My Watchlist
Indicators
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sage Therapeutics, Inc. - Common Stock (NQ: SAGE )

7.260 +0.010 (+0.14%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,777,579
Open 7.350
Bid (Size) 7.250 (3)
Ask (Size) 7.830 (12)
Prev. Close 7.250
Today's Range 7.250 - 7.420
52wk Range 4.620 - 27.39
Shares Outstanding 59,762,106
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Deal Dispatch: Sage And Silvus Are Up For Sale, MrBeast Secures $20B For TikTok
Sage Therapeutics rejects Biogen deal offer; Silvus Technologies considers sale/IPO; Allakos downsizes; MrBeast bids on TikTok. 
Via Benzinga
Sage Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025
From Sage Therapeutics, Inc.
Via Business Wire

Performance

YTD
+25.61%
+25.61%
1 Month
-3.20%
-3.20%
3 Month
+15.24%
+15.24%
6 Month
-7.63%
-7.63%
1 Year
-69.53%
-69.53%

More News

Read More
Biogen Rises On FDA Nod for Alzheimer's Drug Dosing Regimen, But Sage Deal Fallout Irks Retail
Via Stocktwits
Exposures Product Safety
Sage Therapeutics Board of Directors Initiates Review of Strategic Alternatives and Rejects Biogen’s Unsolicited Acquisition Proposal
From Sage Therapeutics, Inc.
Via Business Wire
Where Sage Therapeutics Stands With Analysts
Via Benzinga
Where Sage Therapeutics Stands With Analysts
Via Benzinga
Deal Dispatch: Biden Punts TikTok Ban To Trump, Plus Another Legacy Retailer Goes Bankrupt
Via Benzinga
Topics Government
Exposures Political
Stocks to Watch in 2025: PHIO, LPTH, KAVL, Promising Innovations, Growth Opportunities, Etc. … more inside
Via AB Newswire
Topics Regulatory Compliance
Exposures Legal Regulatory
Sage Therapeutics Stock Eyes Best Day In 5 Years On Biogen’s Unsolicited Bid: Retail Piles In
Via Stocktwits
Exposures Product Safety
Biogen Bid For Sage Therapeutics Could Strengthen Neurology Strategy: Analysts
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For Sage Therapeutics
Via Benzinga
Crude Oil Surges 3%; Abercrombie & Fitch Shares Plunge
Via Benzinga
Exposures Fossil Fuels
Intra-Cellular Therapies, Standard BioTools, SI-BONE And Other Big Stocks Moving Higher On Monday
Via Benzinga
Why Is Depression-Focused Sage Therapeutics Stock Surging Higher On Monday?
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why Sage Therapeutics Shares Are Trading Higher By Over 34%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Sage Therapeutics to Present 2025 Strategic Focus at 43rd Annual J.P. Morgan Healthcare Conference
From Sage Therapeutics
Via Business Wire
Sage Therapeutics Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025
From Sage Therapeutics
Via Business Wire
Sage Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference
From Sage Therapeutics, Inc.
Via Business Wire
This Palo Alto Networks Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
Via Benzinga
After Failed Alzheimer's Study, Sage Therapeutics' Dalzanemdor Flunks Another Study In Patients With Inherited Brain Disorder
Via Benzinga
Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington’s Disease
From Sage Therapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Sage Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Pipeline and Business Updates
From Sage Therapeutics, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.